NeuroScientific Biopharmaceuticals Ltd - Final report received for glaucoma study
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)

Final report received for glaucoma study


What's happened?

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB, “NeuroScientific”) has announced it has received the Final Report from its recently completed glaucoma animal study.

What are the key highlights?

  1. Neuroscientific’s lead drug candidate, called EmtinB, demonstrated neuroprotection across multiple highly relevant study end points.
  2. EmtinB did not cause any toxicity in the tissues analysed during the study, as evidenced by negative results for both TUNEL and Caspase 3 toxicity biomarkers.
  3. NeuroScientific is progressing the safety and toxicology program of EmtinB to be concluded in the second half of this year with first human studies scheduled for later this year.


Please refer to the announcement linked below for further details.

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in NeuroScientific Biopharmaceuticals Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:NSB

    On your online investment platform search for the stock ticker code ASX:NSB to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.